Currently, k-Ras (KRAS) mutation testing is recommended for CRC patients with advanced metastatic disease in order to predict the resistance to epidermal growth factor receptor (EGFR)-targeting therapy [27]. Here, KRAS is linked to colorectal carcinoma.